43rd week of 2012 patent applcation highlights part 46 |
Patent application number | Title | Published |
20120270852 | PHENYL OR PYRIDINYL-ETHYNYL DERIVATIVES - The present invention relates to ethynyl derivatives of formula I | 2012-10-25 |
20120270853 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2012-10-25 |
20120270854 | Antiviral Compounds - Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C. | 2012-10-25 |
20120270855 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR - Thieno- and furo-pyrimidine compounds are described, which are useful as H | 2012-10-25 |
20120270856 | HETEROARYLOXY QUINAZOLINE DERIVATIVES - Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. | 2012-10-25 |
20120270857 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | 2012-10-25 |
20120270858 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling - The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and pathologic angiogenesis. | 2012-10-25 |
20120270859 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER - The present invention encompasses compounds of general formula (1) | 2012-10-25 |
20120270860 | METHODS FOR TREATING OR PREVENTING ALCOHOL-RELATED DISORDERS OR CRAVING-RELATED DISORDERS - The invention provides methods for treating or preventing alcohol-related disorders or craving-related disorders comprising administering an effective amount of N-acetylcysteine or a pharmaceutically acceptable salt thereof to a patient to treat or prevent the alcohol or craving disorders. Methods for enhancing drug delivery and improving treatment outcomes are also described. | 2012-10-25 |
20120270861 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto - The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2012-10-25 |
20120270862 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES - The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzo-diazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity. | 2012-10-25 |
20120270863 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS - The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders. | 2012-10-25 |
20120270864 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS - The present invention relates to compounds of Formula (I): | 2012-10-25 |
20120270865 | HETEROCYCLIC COMPOUND - Provision of a prophylactic or therapeutic agent for diabetes, which has superior efficacy.
| 2012-10-25 |
20120270866 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS - Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders. | 2012-10-25 |
20120270867 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS - The invention relates to the novel materials of formula (I), where: R1 is an optionally substituted aryl or heteroaryl; R is an H or, when formed with R1, a 5- or 6-member ring fused with an aryl or heretoaryl group optionally containing one or more of O, S, N, NH, and Nalk, being optionally substituted; R2 and R3 are, independently, an H, Hal, or alkyl optionally substituted by one or more Hal; R4 is H; and R5 is an H or alkyl optionally substituted by one or more halogen atoms. Said materials being in any isomeric form and the salts thereof, and are intended for drugs, particularly AKT(PKB) phosphorylation inhibitors. | 2012-10-25 |
20120270868 | RHO KINASE INHIBITORS - The present invention relates to compounds of formula (I): | 2012-10-25 |
20120270869 | PYRIDYL DERIVATIVES AS CFTR MODULATORS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2012-10-25 |
20120270870 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists - Diclosed are CCR1 receptor antagonists of the formula (I) | 2012-10-25 |
20120270871 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES - Pyrrolopyridinylpyrimidin-2-ylamine derivatives of the formula (I), in which R | 2012-10-25 |
20120270872 | Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxam- ide - This invention relates to three crystalline forms of N—[3-fluoro-4-((6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl|oxy)phenyl]—N′—(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. Compound (I), designated as Form A, Form B, and Form C. The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline form of Compound (I) and a pharmaceutically acceptable excipient. | 2012-10-25 |
20120270873 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME - The present invention provides adamantyl-diamide derivatives of formula (I): | 2012-10-25 |
20120270874 | Biaryl Compositions and Methods for Modulating a Kinase Cascade - The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention relates to compounds of the formula I: | 2012-10-25 |
20120270875 | PYRIMIDINE AMIDE COMPOUNDS - Provided herein are compounds of the formula (I): | 2012-10-25 |
20120270876 | Treatment of Conditions Through Pharmacological Modulation of the Autonomic Nervous System - Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods. | 2012-10-25 |
20120270877 | IRE-1alpha INHIBITORS - The invention provides compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. | 2012-10-25 |
20120270878 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy. | 2012-10-25 |
20120270879 | Heterocyclic Compounds As CCR1 Receptor Antagonists - Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I). | 2012-10-25 |
20120270880 | PYRROLO [2,3-D] PYRAZIN-7-YLPYRIMIDINE COMPOUNDS - Pyrrolo[2,3-d]pyrazin-7-ylpyrimidine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours. | 2012-10-25 |
20120270881 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS - Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y | 2012-10-25 |
20120270882 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES - Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia. | 2012-10-25 |
20120270883 | USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE - The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments. | 2012-10-25 |
20120270884 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors - The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-IO. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more MMPs or ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm. The invention also comprises methods of treating aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm utilizing the compounds of the invention in conjunction with inhibitors of angiotensin II, including angiotensin II receptor blockers and angiotensin converting enzyme inhibitors, and cyclophillin inhibitors. | 2012-10-25 |
20120270885 | CHEMICAL COMPOUNDS - The use of a compound of formula I | 2012-10-25 |
20120270886 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X | 2012-10-25 |
20120270887 | Method Of Inhibiting Myopia And Application Of An Adenylyl Cyclase Inhibitor As A Drug For inhibiting Myopia - Methods for inhibiting myopia are disclosed. A method for inhibiting myopia includes reducing a level of an intraocular cAMP in a subject. The level of the intraocular cAMP is reduced by injecting an adenylyl cyclase inhibitor to achieve the inhibition of myopia in the subject. In one method, the adenylyl cyclase inhibitor is SQ22536. | 2012-10-25 |
20120270888 | PHARMACEUTICAL COMPOSITIONS OF RALTEGRAVIR, METHODS OF PREPARATION AND USE THEREOF - Disclosed are pharmaceutical compositions comprising HIV integrase strand transfer inhibitor. More particularly, oral pharmaceutical compositions of raltegravir or its pharmaceutically acceptable salts and process for preparing and use of the same are disclosed. | 2012-10-25 |
20120270889 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE - Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses. | 2012-10-25 |
20120270890 | Methods of Pancreatic Beta Cell Regeneration - Disclosed are new methods for pancreatic β-cell regeneration and the methods for identifying adult pancreatic endocrine stem cells and the methods for identifying the existence of differentiation processes from adult pancreatic endocrine stem cells toward pancreatic β-cell fate and a new animal model for pancreatic β-cell regeneration. The present invention can be utilized in screening and development of new medicines and therapy protocols for diabetes. | 2012-10-25 |
20120270891 | Salts of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes. | 2012-10-25 |
20120270892 | Aminopyrimidine Kinase Inhibitors - Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. | 2012-10-25 |
20120270893 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS - The invention provides a compound of Formula (I) | 2012-10-25 |
20120270896 | Antineoplastic Combinations Containing HKI-272 and Vinorelbine - A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described. | 2012-10-25 |
20120270897 | ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2012-10-25 |
20120270898 | SULFONAMIDE COMPOUND AND CRYSTAL THEREOF - (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like. | 2012-10-25 |
20120270899 | Compositions and Methods for Treating Cardiovascular Diseases - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions. | 2012-10-25 |
20120270900 | NOVEL METHOD OF TREATMENT - The present application discloses a method for the treatment or for alleviating the symptoms of a cancer in a subject comprising the steps of a) determining the level of Nicotinic acid phosphoribosyltransferase (NAPRT) in said subject; and b) 1) in the event of a level of NAPRT which is lower than a predetermined threshold value, treating said subject sequentially/simultaneous with i) an effective amount of a nicotinamide phosphoribosyltransferase inhibitor (NAMPRTi), and ii) an effective amount of a nicotinic acid, a nicotinic acid precursor or a prodrug of nicotinic acid; or 2) in the event of a level of NAPRT which is higher than or equal to a predetermined threshold value, treating said subject with i) an effective amount of a NAMPRTi in the absence of sequential/simultaneous treatment with ii) an effective amount of a nicotinic acid, a nicotinic acid precursor or a prodrug of nicotinic acid. | 2012-10-25 |
20120270901 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia): | 2012-10-25 |
20120270902 | N-substituted benzene sulfonamides - The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. | 2012-10-25 |
20120270903 | INTRANASAL SPRAY DEVICE CONTAINING PHARMACEUTICAL COMPOSITION - An intranasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C | 2012-10-25 |
20120270904 | CO-CRYSTAL OF 4-FURAN-2(5H)-ONE WITH OXALIC ACID AND USE THEREOF AS PESTICIDE - The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one with oxalic acid, and also to processes for preparation thereof and use. | 2012-10-25 |
20120270905 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF - The present invention relates to novel fluorinated 2,6-dialkyl-3,5-dicyano-4-(1H-indazol-5-yl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders. | 2012-10-25 |
20120270906 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF - A method relieves both nociceptive pain and neuropathic pain and has fewer side effects. The compound includes cyclohexane derivatives represented by the following compound, or pharmaceutically acceptable salts thereof or prodrugs thereof. | 2012-10-25 |
20120270907 | THERAPEUTIC USES OF NICOTINE - The uses of nicotine, analogues, precursors or derivatives thereof for treatment of inflammatory, infectious, candidal or degenerative diseases of the joint, central nervous system, kidney, lung, and liver, depression, obesity, bone disease and the like are described. The various diseases, disorders or conditions can be improved by means of intensification of the actions of α-MSH, whose release is affected by the use of nicotine, analogues, precursors or derivatives thereof, which can increase and/or reduce the bioavailability of α-MSH in blood and/or central or peripheral tissues to accentuate or diminish the effect of the α-MSH for therapeutic and/or prophylactic purposes. | 2012-10-25 |
20120270908 | SUBSTITUTED 3 -HYDROZYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF - Therapeutic compounds of formula (I) wherein R1 is selected from the group consisting of C | 2012-10-25 |
20120270909 | METHOD OF INHIBITING HARMFUL MICROORGANISMS AND BARRIER-FORMING COMPOSITION THEREFOR - In an embodiment, the barrier-forming composition includes a carbohydrate gum, a humectant, and an antimicrobial agent. The composition furthermore meets the following requirements: about 0.01%≦C≦about 0.4%; about 4.5%≦H≦about 65%; and 0.050% | 2012-10-25 |
20120270910 | PHARMACEUTICAL CONTAINING PPAR-DELTA AGONIST - Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoroethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. | 2012-10-25 |
20120270911 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS - Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity. | 2012-10-25 |
20120270912 | Substituted Indolealkanoic Acids - Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis. | 2012-10-25 |
20120270913 | COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASES - The present invention provides: a composition for controlling plant diseases comprising, as active ingredients, ethaboxam and penflufen; a method for controlling plant diseases which comprises applying effective amounts of ethaboxam and penflufen to a plant or soil for growing plant; and so on. | 2012-10-25 |
20120270914 | SPLIT-LUCIFERASE C-MYC SENSOR AND USES THEREOF - A split luciferase-based sensor system was developed to noninvasively monitor and image phosphorylation-mediated c-Myc activation, in which the complementation of the split FL is induced by phosphorylation-mediated interaction between GSK3β and c-Myc. The complemented luciferase activity resulting from this interaction is specific to c-Myc phosphorylation and correlated with the steady-state and temporal regulation of c-Myc phosphorylation in cell culture. The sensor system also allows monitoring of c-Myc—targeted drug efficacy in intact cells and living animals. This new imaging sensor can provide insight into the role of functional c-Myc in cancer biology and is useful for the discovery and development of specific anti-c-Myc drugs. | 2012-10-25 |
20120270915 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN - Compounds of Formula 1 are described herein. These compounds may be administered to a patient for treatment of suffering from pain or other FAAH mediated conditions. | 2012-10-25 |
20120270916 | TOPICAL FORMULATIONS FOR TREATING NEUROPATHY - Compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy are described. | 2012-10-25 |
20120270917 | ADAMANTANE ANALOGS - Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. | 2012-10-25 |
20120270918 | Pyrazole Derivatives, Preparation Thereof, and Therapeutic Use Thereof - The invention relates to pyrazole derivatives of general formula (I): | 2012-10-25 |
20120270919 | PROTEASOME INHIBITORS - Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation. | 2012-10-25 |
20120270920 | COMPOSITIONS AND METHODS FOR TREATMENT OF POUCHITIS - The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual | 2012-10-25 |
20120270921 | Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus - The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus. | 2012-10-25 |
20120270922 | Antiangiogenic Agent and Method for Inhibition of Angiogenesis - This invention provides an antiangiogenic agent having a higher treatment effect than those of conventional antiangiogenic agents, and a method for inhibiting angiogenesis using the same. An antiangiogenic agent comprising at least one miRNA type selected from the group consisting of miRNAs, pre-miRNAs, and pri-miRNAs, each having a miRNA activity on VE-cadherin. | 2012-10-25 |
20120270923 | NATRIURETIC PEPTIDE RECEPTOR AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCER - The invention pertains to biomarkers for clinical detection of malignancies, especially for early detection of cancers. More specifically, this invention pertains to the role of Natriuretic Peptide Receptor A (NPRA) in cancer (e.g., tumor) progression. Thus, the invention includes materials and methods for the detection and prognosis of malignancies. The invention also pertains to methods for treating malignancies. | 2012-10-25 |
20120270924 | Oligomeric Compounds For The Modultion of HIF-1A Expression - Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof. | 2012-10-25 |
20120270925 | ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59. | 2012-10-25 |
20120270926 | siRNA Targeting Apoliprotein (APOB) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB. | 2012-10-25 |
20120270927 | Polyamides For Nucleic Acid Delivery - A new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications, including, a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response is provided. Complexes including a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells is also provided. The cellular delivery molecules may include one or more polymers, e.g., polyamides, dendritic macromolecules and carbohydrate-containing degradable polyesters. | 2012-10-25 |
20120270928 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 2012-10-25 |
20120270929 | MODULATION OF TTC39 EXPRESSION TO INCREASE HDL - Provided herein are methods, compounds, and compositions for reducing expression of a TTC39 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL and/or decreasing PCSK9 in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate cardiovascular disease, or a symptom thereof. | 2012-10-25 |
20120270930 | METHODS AND COMPOSITIONS FOR DYSFERLIN EXON-SKIPPING - The disclosure provides methods and compositions for inducing exon-skipping in a dysferlin pre-mRNA useful, e.g., in restoring function in a dysferlin deficiency. The disclosure also provides improved methods and compositions for generally inducing exon-skipping in a pre-mRNA. | 2012-10-25 |
20120270931 | STABLE PHARMACEUTICAL FORMULATIONS COMPRISING LUBIPROSTONE - Provided is a pharmaceutical formulation comprising lubiprostone and at least one propylene glycol ester. The propylene glycol ester is typically selected from the group consisting of: propylene glycol mono-ester of lauric acid, propylene glycol mono-ester of caprylic acid, propylene glycol mono-ester of capric acid, propylene glycol di-ester of lauric acid, propylene glycol di-ester of caprylic acid and propylene glycol di-ester of capric acid. | 2012-10-25 |
20120270932 | Personal Care Compositions with Improved Hyposensitivity - The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil. | 2012-10-25 |
20120270933 | LIQUID STATIN FORMULATION - The present invention relates to compositions and methods for liquid statin products suitable for use in a person or animal. The invention provides stable liquid formulations containing a statin and at least one solubilizer. Methods for the oral administration of statin formulations are also provided by the invention. | 2012-10-25 |
20120270934 | PROSTACYCLIN DERIVATIVES - This invention relates to novel prostacyclin derivatives and acceptable salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors. | 2012-10-25 |
20120270935 | FORMULATIONS - An antimicrobial and/or anti-acne formulation containing either usnic acid or an usnate, together with (a) a primary solvent or solvent system in which the usnic acid or usnate is at least partially dissolved; (b) a glycol; and (c) a hydrophobic fatty acid, fatty alcohol or derivative thereof. The formulation may also contain (d) an alkylene glycol derivative. | 2012-10-25 |
20120270937 | LINEAR SELF-ELIMINATING OLIGOMERS - The present invention relates to a linear self-eliminating oligomer comprising one or more cleavable triggers, linker units, effector units and a carrier, and a pharmaceutical composition comprising said oligomer. | 2012-10-25 |
20120270938 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN - A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and | 2012-10-25 |
20120270939 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS - Methods, formulations, and compositions for the treatment of amyloidosis are described. | 2012-10-25 |
20120270940 | Closthioamides - This invention relates to the field of biologically active compounds and specifically to closthioamides, pharmaceutical compositions comprising these compounds, and their use as antibiotic, antifungal, and/or cytotoxic agent. | 2012-10-25 |
20120270941 | TOPICAL APPLICATION OF TRAVOPROST FOR COMBATING HAIR LOSS - Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours. | 2012-10-25 |
20120270942 | Spreading Active Agricultural Agents - Disclosed herein is a device for the application of agricultural active agents, wherein the device is suitable to be brought to the site of action in a manner temporally and spatially separated from the production process, and comprises a dispenser and non-water-soluble nanofibers and/or mesofibers charged with agricultural active agents. The polymers from which the nanofibers and/or mesofibers are made are preferably biodegradable. The agricultural active agents are selected from fungicides, herbicides, batericides, plant growth regulators and plant nutrients. These are preferably pheromones, kairomones and signaling substances. Furthermore, a method for the production of this device is disclosed, wherein the nanofibers and/or mesofibers charged with active agents are produced via electrospinning. The device is suitable to be used to bring agricultural active agents to the site of action in a manner temporally and spatially separated from the production of this device. The application is suitable to be carried out mechanically or automatically. This is preferably agricultural land used for fruit growing, viticulture, gardening or a commercial row crop. The device according to the present invention is particularly suitable to be used for the regulation of arthropods. | 2012-10-25 |
20120270943 | D-aspartic Acid Pro-nutrients with Improved Solubility Characteristics - D-aspartic acid is prepared as its hydrochloride salt or as the hydrochloride salt of its diethyl ester, thereby providing soluble forms of D-aspartic acid that are readily taken up by a human body via its digestive tract. The D-aspartic acid is administered as pills, capsules, powdered drink mixes, beverages, confectionaries, syrups, chewable tablets, nasal sprays, or injectable formulations. | 2012-10-25 |
20120270944 | ANTIOXIDANTS AND VEGETABLE OILS AS STABILIZERS OF INSECT SEMIOCHEMICALS - Semiochemicals are combined with oils and/or antioxidants in order to control and maintain the necessary threshold release rates of the semiochemicals (such as attractants or repellents) from release devices for optimal activity/performance, for the reduction or elimination of semiochemical oxidation, isomerization, breakdown and polymerization, and also for stabilizing and/or protecting the active semiochemical ingredients. | 2012-10-25 |
20120270945 | METHOD FOR MODULATING CYTOKINE ACTIVITY - The present invention relates to a method for modulating cytokine activity, immunomodulation or treating esophagitis comprising an administration of a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating cytokine activity, immunomodulation or treating esophagitis comprising a fatty acid derivative. | 2012-10-25 |
20120270946 | CRYSTALLINE FORM OF BIMATOPROST, PREPARATION METHOD AND USE THEREOF - The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2θ are 3.2+0.2°, 5.5+0.2°, 11.4+0.2°, 16.7+0.2°, 17.6+0.2°, 19.9+0.2°, 20.8±02° and 22.8+0.2° in the X-ray powder diffraction pattern of the crystalline form A. | 2012-10-25 |
20120270947 | Short Telomere Length on Chromosome 9P is Strongly Associated with Breast Cancer Risk - Disclosed are compositions and methods related to assessing the risk of cancer, such as breast cancer, through analyzing the length of telomeres, such as chromosome 9p telomere, such as the short arm of the 9p telomere. If the 9p arm is shorter than normal, the risk of cancer is increased. | 2012-10-25 |
20120270948 | POLYMORPHISIMS IN THE HUMAN CYP2D6 GENE PROMOTER REGION AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to intermediate metabolization of drugs are described. In addition, kits comprising oligonucleotides hybridizing to the CYP2D6 promoter and/or being capable of being extended into this region useful for diagnosing subjects that are ultrarapid or intermediate metabolizer of drugs are provided. | 2012-10-25 |
20120270949 | MELT-GRANULATED CINACALCET - The invention relates to an intermediate obtainable by the melt-extrusion of (i) cinacalcet or a pharmaceutically acceptable salt thereof with (ii) a matrix former, and oral dosage forms, especially tablets containing the intermediates of the invention. The invention further relates to a method of preparing the tablets of the invention. Finally, the invention relates to the use of a matrix former and a wicking agent for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 2012-10-25 |
20120270950 | ALKALINE DECOMPOSITION PRODUCT OF HOP EXTRACT AND USE THEREOF - According to the present invention, there are provided a food and a food additive obtained using an alkaline decomposition product of a hop extract, and an agent for suppressing fat accumulation or for suppressing weight gain comprising the same as an active ingredient. | 2012-10-25 |
20120270951 | NOVEL ANTI-INFLAMMATORY CYCLOOXYGENASE INHIBITORS - Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition. | 2012-10-25 |
20120270952 | METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE - This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) | 2012-10-25 |
20120270953 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFECTION OR INFECTIOUS COLONIZATION OF THE EYELID, OCULAR SURFACE, SKIN OR EAR - The instant invention provides methods and compositions for the treatment of infection or infectious colonization of the eyelid and/or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders. | 2012-10-25 |
20120270954 | METHODS FOR MAINTAINING EYE HEALTH AND AMELIORATING OPTHALMIC MALADIES IN CANINES - The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in canines by administering to the canines an ophthalmic malady ameliorating amount of one or more carotenes. Generally, the carotenes are administered to the canines in amounts of from about 0.1 to about 5000 mg or in amounts of from about 0.1 to about 500 mg per day to ameliorate maladies such as impaired vision, cataracts, cloudy eye, retinal degeneration, eye injury caused by radiation, reducing or preventing a decline of social interaction, promoting overall health and wellness, improving the quality of life, and extending the prime for canines. | 2012-10-25 |